---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-035144"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:12:11.275589+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LIXTE receives USPTO Notice of Allowance for patent covering LB-100 with cancer immunotherapies

## Summary
- U.S. Patent application 16/467,721 titled 'Oxabicycloheptanes for Modulation of Immune Response' allowed.
- Patent covers combining LIXTE's LB-100 PP2A inhibitor with various innovative cancer immunotherapies.
- CEO Bastiaan van der Baan says patent bolsters IP portfolio and commitment to cancer innovation.
- LB-100 is being tested in clinical trials with Roche's atezolizumab (colon cancer) and GSK's dostarlimab (ovarian cancer).
- Follows exclusive patent license agreement earlier this year with NINDS and NCI of the NIH.

## SEC filing metadata
- accession: 0001493152-24-035144
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224035144/0001493152-24-035144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224035144/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-035144
- JSON: https://secwatch.observer/filing/0001493152-24-035144.json
- Plain text: https://secwatch.observer/filing/0001493152-24-035144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.